Oric Pharmaceuticals/$ORIC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Ticker
$ORIC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
122
ISIN
US68622P1093
Website
ORIC Metrics
BasicAdvanced
$786M
-
-$1.88
1.36
-
Price and volume
Market cap
$786M
Beta
1.36
52-week high
$14.67
52-week low
$3.90
Average daily volume
1.6M
Financial strength
Current ratio
12.002
Quick ratio
11.564
Long term debt to equity
2.504
Total debt to equity
3.967
Profitability
EBITDA (TTM)
-145.475
Management effectiveness
Return on assets (TTM)
-30.87%
Return on equity (TTM)
-48.45%
Valuation
Price to book
2.98
Price to tangible book (TTM)
2.98
Price to free cash flow (TTM)
-5.598
Free cash flow yield (TTM)
-17.86%
Free cash flow per share (TTM)
-164.71%
Growth
Earnings per share change (TTM)
5.36%
3-year earnings per share growth (CAGR)
-5.23%
What the Analysts think about ORIC
Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.
Bulls say / Bears say
ORIC Pharmaceuticals has secured significant partnerships with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for prostate cancer treatment, indicating strong industry confidence in their pipeline. (stocktitan.net)
The company reported a robust cash position of $282.4 million as of September 30, 2024, expected to fund operations into late 2026, providing financial stability for ongoing and future projects. (stocktitan.net)
Analysts have maintained a 'Buy' rating for ORIC Pharmaceuticals, with an average price target of $18.29, reflecting positive expectations for the company's stock performance. (americanbankingnews.com)
Insider selling activity, including the CEO selling 24,660 shares and the CFO selling 8,851 shares in December 2024, may raise concerns about internal confidence in the company's future prospects. (investing.com)
The company's R&D expenses increased by $8.8 million to $31.2 million in Q3 2024 compared to Q3 2023, which could impact profitability if not offset by future revenues. (stocktitan.net)
Despite a strong cash position, the company reported a net loss of $36.31 million in Q4 2024, highlighting ongoing financial challenges. (google.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
ORIC Financial Performance
Revenues and expenses
ORIC Earnings Performance
Company profitability
ORIC News
AllArticlesVideos
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital
Benzinga·3 weeks ago
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oric Pharmaceuticals stock?
Oric Pharmaceuticals (ORIC) has a market cap of $786M as of June 20, 2025.
What is the P/E ratio for Oric Pharmaceuticals stock?
The price to earnings (P/E) ratio for Oric Pharmaceuticals (ORIC) stock is 0 as of June 20, 2025.
Does Oric Pharmaceuticals stock pay dividends?
No, Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Oric Pharmaceuticals dividend payment date?
Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders.
What is the beta indicator for Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.